| Document |
Document Title |
|
WO/2020/153800A9 |
The present invention relates to a composition for preventing or treating triple negative breast cancer, containing tumor infiltrating lymphocytes as an active ingredient. According to the present invention, tumor infiltrating lymphocyte...
|
|
WO/2021/001542A1 |
A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and/or decreasing the a...
|
|
WO/2021/001660A1 |
There is provided an in vitro three dimensional cell construct for use as a model of the avian intestine derived from avian intestinal tissue comprising avian cells organised into intestinal villi and crypts. Suitably the construct compr...
|
|
WO/2021/003222A1 |
Disclosed herein are microfluidic devices that may be used to mimic human organ systems, in particular, pancreatic function, and methods of using same. In particular, disclosed are microfluidic devices that may include a first chamber ha...
|
|
WO/2021/002554A1 |
The present invention relates to: a composition for promoting the proliferation of pluripotent stem cells, containing, as an active ingredient, cP1P or a pharmaceutically acceptable salt thereof; and a composition added to a stem cell cu...
|
|
WO/2020/247957A3 |
Disclosed herein are methods for generating mature cardiomyocytes and compositions including mature cardiomyocytes. Also disclosed herein are methods for enhancing maturation of quiescent cardiomyocytes and compositions including mature ...
|
|
WO/2021/001577A1 |
The invention relates to a tissue for use as a transplant, which tissue is allogeneic or xenogeneic and respectively the tissue may express an MHC I molecule that is immunologically incompatible to the transplant recipient and/or may exp...
|
|
WO/2021/003254A1 |
This disclosure provides a cryopreservation medium that includes a tissue extract, and a method of cryopreserving cells and/or tissues using the cryopreservation medium.
|
|
WO/2021/002312A1 |
[Problem] To provide: an anti-EphA4 antibody that can bind to EphA4 and promote the cleavage of EphA4; and a pharmaceutical composition comprising said antibody as an active ingredient. [Solution] A mouse anti-EphA4 antibody having bindi...
|
|
WO/2021/002358A1 |
A culture apparatus is provided with: a culture vessel 12 in which a liquid culture medium is accommodated; a culture vessel shaking section which shakes the culture vessel 12 so as to agitate the liquid culture medium CS in the culture ...
|
|
WO/2021/002448A1 |
The present invention provides a method for producing a culture medium composition for suspension culturing adherent cells, said method including the following steps: (i) a step for supporting an extracellular matrix on nanofibers comp...
|
|
WO/2021/003352A1 |
The insant disclosure is directed to a method for vascularizing a pancreatic islet comprising culturing the pancreatic islet or Beta-cells with an endothelial cell comprising an exogenous nucleic acid encoding an ETV2 transcription facto...
|
|
WO/2020/243416A3 |
Provided herein are methods for obtaining tumor-targeting T cells, as well as for identifying tumor-targeting TCRs.
|
|
WO/2021/002571A1 |
The present invention relates to a method for mass-producing plant exosomes. The method of the present invention can extract high-purity plant exosomes from a large amount of raw plants by using centrifugation and TFF, which can treat a ...
|
|
WO/2021/001510A1 |
The invention provides two newly identified blood group antigens (BGA), analytical processes for identifying the presence of the nucleotide sequence encoding these BGA and analytical processes for identifying these BGA proteins and an an...
|
|
WO/2021/002037A1 |
A centrally crowded state (83) of a cell population is formed by subjecting a culture container to a shaking motion prior to removing the culture medium by suction. In the centrally crowded state (83), cell clusters (84) are separated fr...
|
|
WO/2021/000878A1 |
The present invention provides methods and compositions for identifying, selecting, and/or producing a soybean plant or germplasm resistant to Asian soybean rust using markers, genes and chromosomal intervals derived from Glycine max str...
|
|
WO/2021/002676A1 |
Disclosed are mesenchymal stem cells genetically engineered to express pigment epithelium-derived factor (PEDF), or overexpress PEDF in comparison to parental cells. According to one embodiment, a pharmaceutical composition and a health ...
|
|
WO/2021/003425A1 |
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising a FLT3L polypeptide. Also provided herein are methods of inducing an hematopoiesis in a subject in need thereof comprising administering an extracellula...
|
|
WO/2021/003270A1 |
Described herein are systems and methods relating to cellular micro-masonry. Systems and methods as described herein allow a user to create three-dimensional (3D) structures of cells disposed in a 3D culture medium. Systems and methods a...
|
|
WO/2021/002412A1 |
A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D' region...
|
|
WO/2021/001828A1 |
Compositions and methods for generating insulin-producing beta cells from pluripotent stem cells are provided. The compositions and methods of the present invention involve stepwise differentiation while the differentiating cells are cul...
|
|
WO/2021/003300A1 |
This disclosure relates to compositions including mesenchymal stem or stromal cells (MSCs) that harbor one or more modified RNA molecules encoding a bone morphogenetic protein (BMP), e.g., human BMP, and one or more modified RNA molecule...
|
|
WO/2021/001335A1 |
Methods for evaluating the expression of one or more molecules of interest by cell types of interest within a heterogeneous population of cells are provided, comprising: (i) sorting cells of the heterogeneous population of cells into two...
|
|
WO/2021/003340A1 |
Disclosed are methods of increasing cardiac function in a subject's myocardium comprising: administering a scaffold to the subject's myocardium, wherein the scaffold comprises mesenchymal stem cells (MSCs). Disclosed are methods of resto...
|
|
WO/2021/003188A1 |
The invention relates to a method of cultivating adherent cells in a multiparallel bioreactor, using PET carrier strips, for the optimization of growth and production parameters of adherent cells. The invention also relates to a method o...
|
|
WO/2020/259536A1 |
Provided are a monoclonal antibody-cytokine fusion protein dimer and an application thereof. The monoclonal antibody comprises two heavy chains, the fusion protein dimer comprises a first heavy chain polypeptide chain and a second heavy ...
|
|
WO/2020/264138A1 |
Synthetic, self-replicating RNA vectors comprising sequence encoding at least one immortalization protein, and use of the self-replicating RNA vectors to extend the lifespan of primary cell populations and expand said populations of prim...
|
|
WO/2020/261455A1 |
An embodiment of the present invention is a method for evaluating a cell function of test cells which are stem cells, the method comprising: an image acquisition step (S1, S2) for acquiring a cell image obtained by capturing an image of ...
|
|
WO/2020/259559A1 |
Provided are an immunogenic varicella-zoster virus gE protein mutant and a coding gene thereof. Compared to a wild-type varicella-zoster virus gE protein, the mutant differs in that leucine is mutated into methionine at position 141 of a...
|
|
WO/2020/262551A1 |
An embodiment of the present invention is a method for evaluating a cell function of a target cell that is a stem cell, the method comprising: an image acquisition step (S1, S2) for acquiring a photographed cell image of a target cell; a...
|
|
WO/2020/260697A1 |
The invention concerns a method and a new in vitro cell culture system, wherein the cells, preferably isolated from the human central or peripheral nervous system but also from any other human tissue, are incubated on a new conception ph...
|
|
WO/2020/257922A1 |
Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltra...
|
|
WO/2020/262062A1 |
Provided are: a method for producing a hepatocyte culture, the method comprising a culturing step in which in a porous film having a plurality of apertures in the surface thereof, and communicating pores communicating adjacent apertures ...
|
|
WO/2020/264308A1 |
Human cardiac fibroblasts obtained from induced pluripotent stem cells (iPS cells) are provided for use in analysis, screening programs, and the like.
|
|
WO/2020/258706A1 |
Provided are a combined chromatography apparatus, a seamless connection chromatography method, and a biological agent purification method. The combined chromatography apparatus comprises at least two basic chromatography devices and at l...
|
|
WO/2020/257867A1 |
The present invention relates to methods for the identification of cell culture factors for cell maintenance and cell conversion.
|
|
WO/2020/264455A1 |
Bioreactor systems can include a first frame and a second frame, a well plate, a motor plate, a motor, and a controller. The first frame may define a well plate inset and standoff insets for a first set of metal standoffs. The second fra...
|
|
WO/2020/258083A1 |
Disclosed is a cell culture method, comprising the following steps: first, providing cells and culturing the cells in a culture medium; next, targeting a doubling time interval of the cells and transmitting millimeter wave signals throug...
|
|
WO/2020/258637A1 |
Provided are a kidney transplant donor-specific urine-derived cell and its DNA preparation method, and an application in kidney transplant donor genomics background analysis. The preparation method of the urine-derived cell comprises the...
|
|
WO/2020/257942A1 |
The present invention teaches a method for increasing the yeild of a recombinant protein of interest comprising, transfecting a mammalian cell with both the protein of interest and with full length furin.
|
|
WO/2020/262469A1 |
The present invention relates to a gelatin short fiber which contains gelatin as a main component, and which has an average fiber diameter of 5-400 μm when dispersed in water, and an average fiber diameter of 50-400 μm, and is used to ...
|
|
WO/2020/260714A1 |
The present invention relates to the bioengineering of animal pelts and anti-counterfeit of prime bioengineered pelts and to bioengineered pelts with inseparable molecular signatures for authenticity, timestamping and provenance. The pre...
|
|
WO/2020/260908A1 |
The invention relates to fusion target-binding proteins, such as chimeric antigen receptors (CARs), that comprise a target binding moiety, an intracellular signalling region, and an arginase domain. These proteins confer advantages that ...
|
|
WO/2020/262003A1 |
[Problem] The purpose of the present invention is to provide an oral composition having improved dispersion stability of a Salacia genus plant extract in liquid oil and/or water. [Solution] When nattokinase is included together with a Sa...
|
|
WO/2020/261257A1 |
The present invention provides methods and systems for enhanced production and/or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing vario...
|
|
WO/2020/263919A1 |
Disclosed are methods for identifying neoantigens and methods of treating cancer using neoantigens identified by said methods. The disclosure herein provide for methods for identifying neoantigens that can be used as a target for the tre...
|
|
WO/2020/260875A1 |
The present invention provides a culture medium suitable for culturing T-cells comprising two or more medium supplements selected from an inhibitor of the PI3K/AKT/mTOR pathway, platelet lysate and interleukin 21 (IL-21). It further prov...
|
|
WO/2020/264532A1 |
Provided herein are methods and compositions for treating genetic blood cell diseases, e.g. sickle cell disease and thalassemia, by correcting genetic mutation or inserting exogenous globin gene using CRISPR/Cas system.
|
|
WO/2020/259605A1 |
The present invention relates to formulations containing an anti-CD47/PD-L1 bispecific antibody, and in particular, to pharmaceutical formulations containing an anti-CD47/PD-L1 bispecific antibody, a buffer, a stabilizer, and a surfactan...
|
